Article

RRM2 as a Key Biomarker and Therapeutic Target in Letrozole-Resistant ER+ Breast Cancer: Insights from Bioinformatics and Molecular Docking

2025-03-31

Abstract excerpt

<title>Abstract</title> <p>Letrozole is a first-line aromatase inhibitor for estrogen receptor-positive (ER+) breast cancer; however, resistance develops in 20–30% of patients, limiting therapeutic efficacy. The inability to predict treatment response before therapy initiation remains a significant challenge, as no reliable biomarkers have been established. This study aimed to identify novel prognostic biomarkers...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a1c23cb8-c51d-5728-b615-dec23a0a1692
DOI: 10.21203/rs.3.rs-6183643/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

RRM2 as a Key Biomarker and Therapeutic Target in Letrozole-Resistant ER+ Breast Cancer: Insights from Bioinformatics and Molecular DockingDOI 10.21203/rs.3.rs-6183643/v1Read

Secondary Analysis of Human Bulk RNA-seq Dataset Suggest Potential Mechanisms and Transcriptional Biomarkers for Letrozole Resistance in Estrogen Positive (ER+) Breast CancerSemantic proximity Read

Investigation of the Genomic and Transcriptomic Variations Underlying Tamoxifen Resistance in Breast CancerSemantic proximity Read

A data driven approach to identify ZM-447439 as a potential repurposed drug to overcome tamoxifen-resistance in breast cancerSemantic proximity Read

Data-Driven Discovery of a Key Regulator Cyclin A2 as a Promising Therapeutic Target in Hormone-Sensitive Cancers.Semantic proximity Read

Reversal of endocrine resistance via N6AMT1-NEDD4L pathway-mediated p110α degradationSemantic proximity Read

Molecular Mechanisms and Therapeutic Strategies to Overcome Resistance to Endocrine Therapy and CDK4/6 Inhibitors in Advanced ER+/HER2- Breast CancerSemantic proximity Read

Characterizing novel molecular mechanisms involved in breast cancer tumourigenesis/progression and tamoxifen resistanceSemantic proximity Read

A tumor-agnostic, topology-informed scoring framework for drug repurposing: application to CDK4/6 inhibitor resistance in HR+ breast cancerSemantic proximity Read

Targeted therapies for ER+/HER2- metastatic breast cancerSemantic proximity Read

Functional Analysis of Non-Genetic Resistance to Platinum in Epithelial Ovarian Cancer Reveals a Role for the MBD3-NuRD Complex in Resistance DevelopmentSemantic proximity Read

Gene expression associated with endocrine therapy resistance in estrogen receptor-positive breast cancerSemantic proximity Read

Genomic hallmarks of endocrine therapy resistance in ER/PR+HER2- breast tumoursSemantic proximity Read